WALTHAM,
Mass., Feb. 26, 2025 /PRNewswire/ -- Q32 Bio Inc.
(Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company
focused on developing biologic therapeutics to restore immune
homeostasis, today announced that management will participate in
two upcoming investor conferences in March:
TD Cowen 45th Annual Health Care Conference
Date: Wednesday, March 5, 2025
Presentation Time: 11:50 a.m.
E.T.
Location: Boston, MA
Leerink Partners Global Healthcare Conference
Date: Tuesday, March 11, 2025
Fireside Chat Presentation Time: 11:20 a.m.
E.T.
Location: Miami Beach, FL
A webcast of the presentations will be available on the Events
and Presentations page of Q32 Bio's website at www.Q32Bio.com.
Archived replays will be available for 90 days following the
event.
About Q32 Bio
Q32 Bio is a clinical stage biotechnology company whose science
targets potent regulators of the adaptive immune system to
re-balance immunity in autoimmune and inflammatory diseases.
Q32 Bio is advancing bempikibart (ADX-914), a fully human
anti-IL-7Rα antibody that re-regulates adaptive immune function for
the treatment of autoimmune diseases being evaluated in a Phase 2
program. The IL-7 and TSLP pathways have been genetically and
biologically implicated in driving several T cell-mediated
pathological processes in numerous autoimmune diseases.
For more information, visit www.Q32Bio.com.
Availability of Other Information About Q32 Bio
Investors and others should note that we communicate with our
investors and the public using our company website www.Q32Bio.com,
including, but not limited to, company disclosures, investor
presentations and FAQs, Securities and Exchange Commission filings,
press releases, public conference call transcripts and webcast
transcripts, as well as on X (formerly Twitter) and LinkedIn. The
information that we post on our website or on X or LinkedIn could
be deemed to be material information. As a result, we encourage
investors, the media and others interested to review the
information that we post there on a regular basis. The contents of
our website or social media shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended.
Contacts:
Investors: Brendan
Burns
Media: Sarah Sutton
Argot Partners
212.600.1902
Q32Bio@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-upcoming-march-investor-conferences-302385199.html
SOURCE Q32 Bio
